Patrick H. van Berkel
Research Subjects
Patrick H. van Berkel has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Francesca Zammarchi
ADC Therapeutics (UK) Ltd, London, United Kingdom
45 shared publications - John Anthony Hartley
University College London, London, United Kingdom
40 shared publications - Francesco Bertoni
Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland
38 shared publications - Chiara Tarantelli
Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland
37 shared publications - Filippo Spriano
Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland
37 shared publications - Francois Bertelli
AstraZeneca (MedImmune/Spirogen), London, United Kingdom
37 shared publications
Latest Publications
- Open Access
- 28 October 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF13
Preclinical Characterization of ADCT-241, an Exatecan-Based Antibody–Drug Conjugate against PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein with elevated expression in primary and metastatic prostate cancer compared with normal prostate tissues, with low levels in renal proximal tubules, small intestine, and the brain. PSMA is a clinically validated target and is associated with the progression and aggressiveness of the disease. ADCT-241 is a novel antibody–drug conjugate (ADC) composed of the fully human monoclonal antibody 2A10, directed against PSMA, to which the exatecan-containing PL2202 payload was stochastically conjugated with a drug-to-antibody ratio of 4. 2A10 was selected over J591, as it showed good binding affinity, a better half-life, and superior internalization properties and antitumor activity compared with a J591-based ADC. ADCT-241 showed specific, potent killing of prostate cancer cell lines in vitro and antitumor efficacy in vivo in prostate cancer cell line– and patient-derived xenografts. ADCT-241 showed target-dependent internalization, topoisomerase 1 inhibition, cell-cycle arrest at the G2–M-phase followed by apoptosis-induced cell death, and in vitro bystander activity. In rats and cynomolgus monkeys, ADCT-241 was well tolerated at dose levels ≤150 and 75 mg/kg, respectively, following dosing on days 1 and 22. Circulating serum total antibody, total ADC, and free exatecan concentrations showed good in vivo stability and a half-life of 8 to 10 days in cynomolgus monkeys. ADCT-241 demonstrated potent, specific in vitro and in vivo antitumor activity, and it was stable and well tolerated in rats and cynomolgus monkeys, warranting the progression of ADCT-241 into clinical trials in patients with metastatic castration-resistant prostate cancer.
- 28 October 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF13
Open AccessPreclinical Characterization of ADCT-241, an Exatecan-Based Antibody–Drug Conjugate against PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein with elevated expression in primary and metastatic prostate cancer compared with normal prostate tissues, with low levels in renal proximal tubules, small intestine, and the brain. PSMA is a clinically validated target and is associated with the progression and aggressiveness of the disease. ADCT-241 is a novel antibody–drug conjugate (ADC) composed of the fully human monoclonal antibody 2A10, directed against PSMA, to which the exatecan-containing PL2202 payload was stochastically conjugated with a drug-to-antibody ratio of 4. 2A10 was selected over J591, as it showed good binding affinity, a better half-life, and superior internalization properties and antitumor activity compared with a J591-based ADC. ADCT-241 showed specific, potent killing of prostate cancer cell lines in vitro and antitumor efficacy in vivo in prostate cancer cell line– and patient-derived xenografts. ADCT-241 showed target-dependent internalization, topoisomerase 1 inhibition, cell-cycle arrest at the G2–M-phase followed by apoptosis-induced cell death, and in vitro bystander activity. In rats and cynomolgus monkeys, ADCT-241 was well tolerated at dose levels ≤150 and 75 mg/kg, respectively, following dosing on days 1 and 22. Circulating serum total antibody, total ADC, and free exatecan concentrations showed good in vivo stability and a half-life of 8 to 10 days in cynomolgus monkeys. ADCT-241 demonstrated potent, specific in vitro and in vivo antitumor activity, and it was stable and well tolerated in rats and cynomolgus monkeys, warranting the progression of ADCT-241 into clinical trials in patients with metastatic castration-resistant prostate cancer.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies
Supplementary Fig. S2. The in vitro antitumor activity of ADCT-602 does not correlate with CD22 levels in B-cell lymphomas. This figure shows a correlation of ADCT-602 IC50 values versus (A) cell surface protein expression via absolute fluorescence quantitation with Quantum Simply Cellular microspheres, (B) CD22 RNA expression levels measured via Illumina HT-12 microarrays, and (C) targeted RNA-Seq with the HTG EdgeSeq Oncology Biomarker Panel. On each plot, the x-axes are the ADCT-602 IC50 values presented as log2, and the y-axes are CD22 expression levels presented as log2. Cell lines derived from Hodgkin and T-cell lymphomas have been excluded. IC50 50% inhibitory concentration.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies
Supplementary Fig. S2. The in vitro antitumor activity of ADCT-602 does not correlate with CD22 levels in B-cell lymphomas. This figure shows a correlation of ADCT-602 IC50 values versus (A) cell surface protein expression via absolute fluorescence quantitation with Quantum Simply Cellular microspheres, (B) CD22 RNA expression levels measured via Illumina HT-12 microarrays, and (C) targeted RNA-Seq with the HTG EdgeSeq Oncology Biomarker Panel. On each plot, the x-axes are the ADCT-602 IC50 values presented as log2, and the y-axes are CD22 expression levels presented as log2. Cell lines derived from Hodgkin and T-cell lymphomas have been excluded. IC50 50% inhibitory concentration.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies
Supplementary Fig. S8. Quantification of cynomolgus monkey CD3+, platelets, reticulocytes, and neutrophils after dosing ADCT-602 at 0.6 or 0.9 mg/kg (2 doses, 21 days apart). Data presented as mean ± SEM (each group, n = 3). SEM standard error of mean.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies
Supplementary Fig. S8. Quantification of cynomolgus monkey CD3+, platelets, reticulocytes, and neutrophils after dosing ADCT-602 at 0.6 or 0.9 mg/kg (2 doses, 21 days apart). Data presented as mean ± SEM (each group, n = 3). SEM standard error of mean.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies
Supplementary Fig. S4. Time course of DNA ICL formation in KARPAS-299 cells following a 2-hour treatment with ADCT-602 or SG3199. Results are presented as a mean percentage decrease in OTM ± SD (n = 4). ICL interstrand crosslinking; OTM Olive tail moment.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies
Supplementary Fig. S4. Time course of DNA ICL formation in KARPAS-299 cells following a 2-hour treatment with ADCT-602 or SG3199. Results are presented as a mean percentage decrease in OTM ± SD (n = 4). ICL interstrand crosslinking; OTM Olive tail moment.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies
Supplementary Fig. S5. Kaplan–Meier survival analysis in (A) Ramos and (B) WSU-DLCL2 xenograft models. Kaplan–Meier survival plots showing percentage animal survival (A) over 60 days in Ramos xenograft; and (B) over 59 days in WSU-DLCL2 cancer xenograft. QD once daily.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies
Supplementary Fig. S5. Kaplan–Meier survival analysis in (A) Ramos and (B) WSU-DLCL2 xenograft models. Kaplan–Meier survival plots showing percentage animal survival (A) over 60 days in Ramos xenograft; and (B) over 59 days in WSU-DLCL2 cancer xenograft. QD once daily.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies
Supplementary File. Supervised analyses in B-cell lymphoma cell lines using Illumina HT-12 microarray data This file contains all data, as well as lists of transcripts upregulated (logFC+) or downregulated (logFC−) in the resistant cell lines, gene sets significantly enriched in the 2 groups of cell lines, and IRAK1 expression levels from Illumina microarray.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies
Supplementary File. Supervised analyses in B-cell lymphoma cell lines using Illumina HT-12 microarray data This file contains all data, as well as lists of transcripts upregulated (logFC+) or downregulated (logFC−) in the resistant cell lines, gene sets significantly enriched in the 2 groups of cell lines, and IRAK1 expression levels from Illumina microarray.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies
Supplementary Fig. S6. Group mean body weight of mice in (A) Ramos, (B) WSU-DLCL2, (C) REH, and (D) KARPAS-299 efficacy studies. Data shown as mean body weight (g) ± SEM over time (for each group, n = 10 in A-B, and n = 8 in C-D). QD once daily; Q4D once every 4 days; SEM standard error of mean.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies
Supplementary Fig. S6. Group mean body weight of mice in (A) Ramos, (B) WSU-DLCL2, (C) REH, and (D) KARPAS-299 efficacy studies. Data shown as mean body weight (g) ± SEM over time (for each group, n = 10 in A-B, and n = 8 in C-D). QD once daily; Q4D once every 4 days; SEM standard error of mean.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies
Supplementary Fig. S1. Structure and characterization of ADCT-602. (A) Full-length amino acid sequence of light and heavy chains of hLL2-C220, with the mutations C219S in the light chain and C225V and C228V in the heavy chain indicated in bold. (B) Structure of ADCT-602 with the PBD dimer payload tesirine (SG3249) conjugated at C219 of hLL2-CC20 (C220 according to the EU numbering system) in the heavy chain. (C) ADCT-602 characterized by size exclusion chromatography and by (D) reduced reversed-phase chromatography. L indicates elution of the light chain, whereas H0 and H1 indicate elution of the unconjugated H-chain or H-chain conjugated to SG3249, respectively. (E) RP-HPLC analysis of the reduced tryptic digest of 2 batches of ADCT-602 (red and black traces). Ala alanine; PABC poly(A)-binding protein C-terminal; PBD pyrrolobenzodiazepine; Val valine.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies
Supplementary Fig. S1. Structure and characterization of ADCT-602. (A) Full-length amino acid sequence of light and heavy chains of hLL2-C220, with the mutations C219S in the light chain and C225V and C228V in the heavy chain indicated in bold. (B) Structure of ADCT-602 with the PBD dimer payload tesirine (SG3249) conjugated at C219 of hLL2-CC20 (C220 according to the EU numbering system) in the heavy chain. (C) ADCT-602 characterized by size exclusion chromatography and by (D) reduced reversed-phase chromatography. L indicates elution of the light chain, whereas H0 and H1 indicate elution of the unconjugated H-chain or H-chain conjugated to SG3249, respectively. (E) RP-HPLC analysis of the reduced tryptic digest of 2 batches of ADCT-602 (red and black traces). Ala alanine; PABC poly(A)-binding protein C-terminal; PBD pyrrolobenzodiazepine; Val valine.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies
Supplementary Fig. S9. In vitro cytotoxicity of B12-C220-SG3249 following pretreatment with chidamide for 7 days (Ramos, TMD8, and SU-DHL-4 cell lines).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies
Supplementary Fig. S9. In vitro cytotoxicity of B12-C220-SG3249 following pretreatment with chidamide for 7 days (Ramos, TMD8, and SU-DHL-4 cell lines).